SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~February~~March, 2007

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F X Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______

For Immediateimmediate Release                                           20release                                             12 FebruaryMarch 2007


                                                          SkyePharma PLC (the "Company")

                   Notification                               HOLDING ofIN Major Interests in SharesCOMPANY

LONDON,
On UK,9 20March February 2007, --the SkyePharmaCompany PLCreceived (Nasdaq:notification SKYE;by LSE:Aviva SKP),plc has
receivedof notificationa fromdisclosure
of Legala &notifiable Generalinterest, Groupfollowing Plcthe thatimplementation itof nowthe has an interestTransparency
inDirective, 27of 43,597183,887326 SkyePharmaordinary Ordinaryshares £0.of 10p Shares,each representing 35.6673% of the
votingissued rightsshare capital in respectthe ofCompany.


The issuednotifiable shareinterest capitalcomprises of41,335,090 theordinary Companyshares, representing 5.48%
being a direct holding and 1,848,236 ordinary shares, representing 0.25%, being
                                     -ends-held indirectly.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

                                                                  SkyePharma PLC

                                                                      By: /s/ John Murphy

                                                                       Name: John Murphy
                                                                          Title: Company Secretary

Date: ~~February~~March 2012, 2007

Filing Compare · SKYEPHARMA PLC